BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15070703)

  • 41. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
    Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
    Zent C; Rowley JD; Nucifora G
    Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
    [TBL] [Abstract][Full Text] [Related]  

  • 43.
    Zhen T; Kwon EM; Zhao L; Hsu J; Hyde RK; Lu Y; Alemu L; Speck NA; Liu PP
    Blood; 2017 Nov; 130(22):2431-2442. PubMed ID: 29018080
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia.
    Asou N; Yanagida M; Huang L; Yamamoto M; Shigesada K; Mitsuya H; Ito Y; Osato M
    Blood; 2007 May; 109(9):4023-7. PubMed ID: 17244685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP.
    Izutsu K; Kurokawa M; Imai Y; Ichikawa M; Asai T; Maki K; Mitani K; Hirai H
    Oncogene; 2002 Apr; 21(17):2695-703. PubMed ID: 11965542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.
    Harada H; Harada Y; Niimi H; Kyo T; Kimura A; Inaba T
    Blood; 2004 Mar; 103(6):2316-24. PubMed ID: 14615365
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.
    Mandoli A; Singh AA; Jansen PW; Wierenga AT; Riahi H; Franci G; Prange K; Saeed S; Vellenga E; Vermeulen M; Stunnenberg HG; Martens JH
    Leukemia; 2014 Apr; 28(4):770-8. PubMed ID: 24002588
    [TBL] [Abstract][Full Text] [Related]  

  • 48. c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein.
    Bernardin F; Yang Y; Civin CI; Friedman AD
    Cancer Biol Ther; 2002; 1(5):492-6. PubMed ID: 12496475
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oncogenic potential of the RUNX gene family: 'overview'.
    Ito Y
    Oncogene; 2004 May; 23(24):4198-208. PubMed ID: 15156173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The AML1/ETO fusion protein activates transcription of BCL-2.
    Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11.
    Kundu M; Chen A; Anderson S; Kirby M; Xu L; Castilla LH; Bodine D; Liu PP
    Blood; 2002 Oct; 100(7):2449-56. PubMed ID: 12239155
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
    Osato M
    Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CBFbeta-SMMHC slows proliferation of primary murine and human myeloid progenitors.
    D'Costa J; Chaudhuri S; Civin CI; Friedman AD
    Leukemia; 2005 Jun; 19(6):921-9. PubMed ID: 15815715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutagenesis of the Runt domain defines two energetic hot spots for heterodimerization with the core binding factor beta subunit.
    Zhang L; Li Z; Yan J; Pradhan P; Corpora T; Cheney MD; Bravo J; Warren AJ; Bushweller JH; Speck NA
    J Biol Chem; 2003 Aug; 278(35):33097-104. PubMed ID: 12807883
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
    Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
    Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells.
    Hackanson B; Abdelkarim M; Jansen JH; Lübbert M
    Leukemia; 2010 Apr; 24(4):860-1. PubMed ID: 20090777
    [No Abstract]   [Full Text] [Related]  

  • 57. A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells.
    Zhang YW; Bae SC; Huang G; Fu YX; Lu J; Ahn MY; Kanno Y; Kanno T; Ito Y
    Mol Cell Biol; 1997 Jul; 17(7):4133-45. PubMed ID: 9199349
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AML1/Runx1 recruits calcineurin to regulate granulocyte macrophage colony-stimulating factor by Ets1 activation.
    Liu H; Holm M; Xie XQ; Wolf-Watz M; Grundström T
    J Biol Chem; 2004 Jul; 279(28):29398-408. PubMed ID: 15123671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A conserved cysteine residue in the runt homology domain of AML1 is required for the DNA binding ability and the transforming activity on fibroblasts.
    Kurokawa M; Tanaka T; Tanaka K; Hirano N; Ogawa S; Mitani K; Yazaki Y; Hirai H
    J Biol Chem; 1996 Jul; 271(28):16870-6. PubMed ID: 8663420
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structural and functional characterization of Runx1, CBF beta, and CBF beta-SMMHC.
    Zhang L; Lukasik SM; Speck NA; Bushweller JH
    Blood Cells Mol Dis; 2003; 30(2):147-56. PubMed ID: 12732176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.